Share on facebook Share on Twitter Share on Google Plus Share This
Back to Results

PREVENT


Title Preventing Anthracycline Cardiovascular Toxicity with Statins
Therapeutic Area Breast Cancer, Lymphomas (adult), Congestive Heart Failure
Principal Investigator Jenica Upshaw, MD
Min Age 21 Years
Gender All
Contact Madeleine Arthur
617 636-7651
More Information https://clinicaltrials.gov/ct2/show/NCT01988571

Overview

The overall purpose of this study is to determine if atorvastin (generic for Lipitor) 40mg by mouth daily decreases the chance of developing heart problems in patients receiving Anthracycline based chemotherapy for breast cancer or lymphoma.

Study Details

Inclusion Criteria

  • Stage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer)or Stage I-IV lymphoma
  • Schedule to receive chemotherapy with any anthracycline

Exclusion Criteria

  • Currently using statin therapy
  • Patients with Diabetes
  • Artheroslcerotic cardiovascular disease (ASCVD) defined by history of acute coronary syndromes, heart attack, stable/unstable chest pain, coronary or other arterial revascularization, stroke or peripheral arterial disease presumed to be of atherosclerotic origin.

Study Requirements

This study will last 24 months and will include up to 7 visits to Tufts Medical Center, 3 cardiac MRIs, 2 short telephone interviews, and blood collections.